AR073274A1 - COMPOSITION. USE OF A TRUCKED EIF-5A1 POLINUCLEOTIDE TO INDUCE APOPTOSIS IN CANCEROSE CELLS - Google Patents

COMPOSITION. USE OF A TRUCKED EIF-5A1 POLINUCLEOTIDE TO INDUCE APOPTOSIS IN CANCEROSE CELLS

Info

Publication number
AR073274A1
AR073274A1 ARP090103378A ARP090103378A AR073274A1 AR 073274 A1 AR073274 A1 AR 073274A1 AR P090103378 A ARP090103378 A AR P090103378A AR P090103378 A ARP090103378 A AR P090103378A AR 073274 A1 AR073274 A1 AR 073274A1
Authority
AR
Argentina
Prior art keywords
eif5a1
polynucleotide
composition
truncated
host
Prior art date
Application number
ARP090103378A
Other languages
Spanish (es)
Inventor
Zhenyu Cheng
Catherine Taylor
Zhong Sun
Richard S Dondero
John E Thompson
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/400,742 external-priority patent/US8703929B2/en
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of AR073274A1 publication Critical patent/AR073274A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Abstract

Uso combinado de un ARNsi dirigido contra un gen endogeno para bloquear o silenciar la expresion del gen endogeno en un huésped y al suministro de un polinucleotido que codifica el gen en un vehículo de suministro/vector de expresion al huésped para proporcionar expresion en éste de la proteína codificada por el polinucleotido. Se refiere también a una forma truncada de eIF-5A1 que es util para inducir apoptosis y muerte celular, especialmente en células cancerosas en un mamífero Reivindicacion 1: Una composicion que comprende un polinucleotido eIF5A1 que codifica una proteína eIF5A1 truncada. Reivindicacion 5: La composicion de acuerdo con la reivindicacion 1 caracterizada porque el polinucleotido eIF5A1 está comprendido dentro de un plásmido o vector de expresion. Reivindicacion 16: Un polipéptido eIF5A1 truncado aislado formado por la escision mediada por caspasa de eIF5A1. Reivindicacion 17: Una composicion que comprende un polinucleotido eIF5A1 que codifica una proteína eIF5A1 truncada y un polinucleotido eIF5A1 de longitud completa. Reivindicacion 21: La composicion de acuerdo con la reivindicacion 19 caracterizada porque el polinucleotido eIF5As de longitud completa codifica un eIF5A1 mutante en el cual la mutacion previene o inhibe la hipusinacion por desoxihipusina sintasa y/o en el cual la mutacion está presente en el sitio de ubiquinizacion y/o en el sitio de acetilacion. Reivindicacion 23: La composicion de acuerdo con la reivindicacion 21 que comprende además un ARNsi dirigido contra el 3'UTR de eIF5A. Reivindicacion 30: Un método para inducir apoptosis en una célula cancerosa de mamífero o un tumor de mamífero proporcionando al mamífero las composiciones de la reivindicacion 1. Reivindicacion 32: El método de acuerdo con la reivindicacion 30 caracterizado porque el cáncer es mieloma multiple.Combined use of an siRNA directed against an endogenous gene to block or silence the expression of the endogenous gene in a host and to supply a polynucleotide encoding the gene in a delivery vehicle / expression vector to the host to provide expression therein of the host protein encoded by the polynucleotide. It also refers to a truncated form of eIF-5A1 that is useful for inducing apoptosis and cell death, especially in cancer cells in a mammal. Claim 1: A composition comprising an eIF5A1 polynucleotide encoding a truncated eIF5A1 protein. Claim 5: The composition according to claim 1 characterized in that the eIF5A1 polynucleotide is comprised within a plasmid or expression vector. Claim 16: An isolated truncated eIF5A1 polypeptide formed by caspase-mediated cleavage of eIF5A1. Claim 17: A composition comprising an eIF5A1 polynucleotide encoding a truncated eIF5A1 protein and a full length eIF5A1 polynucleotide. Claim 21: The composition according to claim 19 characterized in that the full-length eIF5As polynucleotide encodes a mutant eIF5A1 in which the mutation prevents or inhibits deoxyhipusine synthase hypusination and / or in which the mutation is present at the site of location and / or at the acetylation site. Claim 23: The composition according to claim 21 further comprising an siRNA directed against the 3'UTR of eIF5A. Claim 30: A method for inducing apoptosis in a mammalian cancer cell or a mammalian tumor by providing the mammal with the compositions of claim 1. Claim 32: The method according to claim 30 characterized in that the cancer is multiple myeloma.

ARP090103378A 2008-09-03 2009-09-02 COMPOSITION. USE OF A TRUCKED EIF-5A1 POLINUCLEOTIDE TO INDUCE APOPTOSIS IN CANCEROSE CELLS AR073274A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9374908P 2008-09-03 2008-09-03
US12/400,742 US8703929B2 (en) 2008-03-07 2009-03-09 Compositions comprising siRNA and plasmids

Publications (1)

Publication Number Publication Date
AR073274A1 true AR073274A1 (en) 2010-10-28

Family

ID=41797839

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103378A AR073274A1 (en) 2008-09-03 2009-09-02 COMPOSITION. USE OF A TRUCKED EIF-5A1 POLINUCLEOTIDE TO INDUCE APOPTOSIS IN CANCEROSE CELLS

Country Status (8)

Country Link
EP (1) EP2331142A4 (en)
JP (1) JP2012501650A (en)
CN (1) CN102202693A (en)
AR (1) AR073274A1 (en)
AU (1) AU2009288092A1 (en)
CA (1) CA2735823A1 (en)
TW (1) TW201023898A (en)
WO (1) WO2010028093A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012165672A (en) * 2011-02-10 2012-09-06 Tottori Univ Artificial nucleic acid conjugate for amplifying single-base recognition ability
WO2013082449A2 (en) * 2011-11-30 2013-06-06 Senesco Technologies, Inc. Treatment of b cell lymphomas
US20150126581A1 (en) * 2012-03-08 2015-05-07 The University Of Western Australia MicroRNAs and Uses Thereof
CN103709238B (en) * 2013-12-18 2015-04-22 北京市农林科学院 Application of poplar salt tolerant gene PtoeIF5A1
JP6639408B2 (en) 2014-11-07 2020-02-05 藤倉化成株式会社 Method for detecting arteriosclerosis and cancer using deoxyhypusine synthase gene as an index
WO2016178233A1 (en) * 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
CN114231551B (en) * 2021-12-24 2023-09-29 云南大学 Application of protein in promoting apoptosis of insect lymphocytes and/or preventing and controlling pests

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522591A (en) * 2004-12-03 2008-07-03 セネスコ テクノロジーズ，インコーポレイティド Apoptosis-specific EIF-5A and polynucleotide encoding the same
AR057234A1 (en) * 2005-12-13 2007-11-21 Senesco Technologies Inc USE OF EIF-5A TO DESTROY MULTIPLE MEILOMA CELLS

Also Published As

Publication number Publication date
TW201023898A (en) 2010-07-01
JP2012501650A (en) 2012-01-26
CA2735823A1 (en) 2010-03-11
EP2331142A2 (en) 2011-06-15
CN102202693A (en) 2011-09-28
WO2010028093A3 (en) 2010-08-05
EP2331142A4 (en) 2012-08-29
WO2010028093A2 (en) 2010-03-11
AU2009288092A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
AR073274A1 (en) COMPOSITION. USE OF A TRUCKED EIF-5A1 POLINUCLEOTIDE TO INDUCE APOPTOSIS IN CANCEROSE CELLS
Parsons et al. USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase β
CL2018001198A1 (en) Methods and compositions for gene editing in hemocytoblasts
PE20130213A1 (en) USEFUL PREDICTIVE MARKERS IN THE TREATMENT OF FRAGILE X SYNDROME (FXS)
BR112014026801A2 (en) 5 - [[4 - [[morpholin-2-yl] methylamino] -5- (trifluoromethyl) -2-pyridyl] amino] pyrazine-2-carbonitrile and therapeutic uses thereof
PE20181206A1 (en) SPECIFIC LIVER CONSTRUCTIONS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE OF THESE
PE20121429A1 (en) NEW ANTITUMORAL USE OF CABAZITAXEL
CL2009000082A1 (en) Nucleic acid encoding anti cd79a or anti cd79b antibodies for the treatment of hematopoietic tumors; vector and host cells comprising them; polypeptide encoded by said nucleic acid, immunoconjugated with the body.
Liu et al. Zebrafish dead end possesses ATPase activity that is required for primordial germ cell development
AR065075A1 (en) VECTORS FOR MULTIPLE EXPRESSION OF GENES
BR112013010855A2 (en) oplophorus-derived luciferases, novel coelenterazine substrates and methods of use
MY173998A (en) Glucosylceramide synthase inhibitors
AR047897A1 (en) COMPOSITIONS AND METHODS THAT USE RNA INTERFERENCE FOR NEMATODE CONTROL
CL2012001539A1 (en) 005-c04 antibody that antagonizes prolactin receptor-mediated signaling; nucleic acid sequence encoding said antibody; expression vector and host cell comprising said nucleic acid sequence; use of the antibody for combination hormonal therapy; pharmaceutical composition comprising the antibody.
CL2011002039A1 (en) Humanized antibody that binds to human cd19; isolated nucleic acid encoding said antibody; vector and host cell; composition and immunoconjugate; method to inhibit the growth of tumor cells expressing cd19.
EA201491470A1 (en) COMPOSITIONS OF FACTOR VIII AND METHODS OF OBTAINING AND USING SIMILAR
ECSP077910A (en) NANOBODIESTM (NANOCUPOS) IMPROVED AGAINST THE ALFA FACTOR OF TUMOR NECROSIS
CL2008003596A1 (en) Enzymatically susceptible phytase, polynucleotide encoding it, expression cassette, vector and host cell comprising said nucleic acid; method of preparing phytase, and compositions comprising it.
Tsai et al. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras
EA201100225A1 (en) NEW REGULATORY ELEMENTS
PE20091378A1 (en) PLEXIND1 AGONIST POLYPEPTIDES
ES2383716T3 (en) Compositions and methods that use RNA interference from a gene of the OPR3 type for nematode control
AR078848A1 (en) INTERFERENCE RNA THERAPEUTIC TECHNOLOGY DIRECTED TO ONCOGEN PDX -1 IN NEUROENDOCRINE TUMORS WHERE PDX-1 IS EXPRESSED
BR112014031526A2 (en) promoters to express a gene in a cell
Lee et al. Decreased mitochondrial OGG1 expression is linked to mitochondrial defects and delayed hepatoma cell growth

Legal Events

Date Code Title Description
FA Abandonment or withdrawal